Lisocabtagene maraleucel (liso-cel; Breyanzi) fostered a better quality of life (QoL) in patients with relapsed/refractory large B-cell lymphoma (LBCL) compared with current standard of care (SOC), according to data from a comparative analysis of the phase 3 TRANSFORM trial (NCT03575351) presented during the 2021 ASH Annual Meeting.1
Using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire 30 items (EORTC QLQ-C30), a linear mixed model for repeated measures (MMRM) group analysis found that those in the liso-cel arm had more favorable overall least square (LS) mean changes from baseline to day 126 vs the SOC arm in most of the domains analyzed.
Evaluable patients who received the CAR T-cell therapy (n = 47) experienced a mean change in cognitive functioning of 2.21 (range, -1.48 to 5.90) vs -2.09 (range, -6.00 to 1.83) in those who received SOC (n = 43); this translated to a difference of 4.30 (range, -0.76 to 9.36) on day 126 from baseline.
Those in the liso-cel arm also experienced a mean change in fatigue of -1.95 (range, -7.40 to 3.51) compared with 3.75 (range, -2.17 to 9.68) in the SOC arm, equating to a difference of -5.70 (range, -13.24 to 1.84) on day 126 from baseline. In these domains, the liso-cel group improved, as the SOC group deteriorated.
Additionally, the liso-cel arm had a mean change in global health status/QoL (GH/QoL) of 3.08 (range, -1.83 to 7.99) from baseline to day 126; the SOC arm experienced a mean change of 0.04 (range, -5.24 to 5.31), resulting in a difference of 3.04 (range, -3.62 to 9.70) between the 2 arms.
The liso-cel group also experienced mean changes in physical functioning and pain of -2.75 (range, -6.76 to 1.25) and -11.14 (range, -16.37 to -5.92), respectively, compared with -2.17 (range, -6.64 to 2.30) and -15.56 (range, -21.25 to -9.88), respectively, for the SOC group. The differences between the 2 arms in physical functioning and pain were -0.58 (range, -6.17 to 5.01) and 4.42 (range, -2.72 to 11.56), respectively.
Individual-level analyses demonstrated that the proportion of patients with meaningful improvement was higher for GH/QoL, and deterioration was lower with liso-cel vs SOC from day 126 to month 6.
At the 6-month mark, 53% of patients in the liso-cel arm reported improvement in GH/QoL, compared with 14% of those in the SOC arm. Eighteen percent of patients in the liso-cel arm reported deterioration of GH/QoL at this time point vs 57% of those on the SOC arm. Furthermore, 47% of patients in the liso-cel group experienced improvement in fatigue at 6 months vs 29% of those in the SOC group. Eighteen percent of patients in the liso-cel arm experienced deterioration regarding fatigue at this time point vs 71% of those in the SOC arm.
It is important to emphasize that higher scores on functionality domains and lower scores on symptom domains indicate a better QoL, presenting study author Jeremy Abramson, MD, of Massachusetts General Hospital Cancer Center, said during the poster presentation of the data.
TRANSFORM enrolled patients between the ages of 18 and 75 years who had aggressive non-Hodgkin lymphoma and who were refractory or relapsed 12 months or less following first-line treatment containing an anthracycline and a CD20-targeted agent. To be eligible for enrollment, patients needed to have an ECOG performance status of 0 or 1, be eligible for hematopoietic stem cell transplantation and have a left ventricular ejection fraction of over 40%. Patients with secondary central nervous system lymphoma were permitted. There was no minimum lymphocyte count.
Participants were randomized 1:1 to receive either SOC comprised of 3 cycles of salvage chemotherapy and BEAM (carmustine, etoposide, cytarabine, and melphalan) plus autologous stem cell transplantation for responding patients, or liso-cel following lymphodepletion treatment. Crossover to the liso-cel arm was permitted for patients who failed SOC treatment. Patients received the CAR T-cell therapy at a dose of 100 x 106CAR-positive T cells.
The primary end point of the trial was event-free survival (EFS), and key secondary end points comprised complete response (CR) rate, progression-free survival (PFS), and overall survival. Other end points of interest included duration of response, objective response rate, PFS on the next line of treatment, safety, and patient-reported outcomes (PROs).
In a prespecified interim analysis of data from TRANSFORM, liso-cel demonstrated highly statistically relevant and clinically meaningful improvement vs SOC regarding the primary end point of EFS, plus secondary end points of CR and PFS.2In the analysis presented during the 2021 ASH Annual Meeting, Abramson reported findings pertaining to QoL.
Investigators evaluated QoL by leveraging the EORTC QLQ-C30 and FACT-LymS tools. The former evaluated cancer-associated symptoms and functioning and is comprised of 30 items that address 15 domains. Primary functional domains of interest that were evaluated in TRANSFORM were GH/QoL, physical functioning, and cognitive functioning. Primary symptom domains of interest were fatigue and pain. The FACT-LymS tool evaluated symptoms that were specific to lymphoma and was comprised of 15 items. With this assessment, higher scores are representative of better QoL.
To assess the between-treatment differences in overall LS mean change from baseline for each primary domain, a MMRM analysis was conducted, and this leveraged data collected up to day 126 for visits with a sample size per are of 10 or more. All analyses were prospectively defined, and the findings reported during the 2021 ASH Annual Meeting are descriptive.
To be eligible for PRO analyses, patients needed to complete a baseline assessment and at least 1 post-baseline assessment. Notably, a similar proportion of patients were included in the EORTC QLQ-C30 analyses sets for liso-cel (51%) and SOC (47%).
In the liso-cel group of 92 patients, 47 were evaluable for the EORTC QLQ-C30 analysis, and 45 were evaluable for the FACT LymS analysis. Notably, 45 patients were not included in the EORTC QLQ-C30 analysis because they did not complete a baseline assessment (n = 28), a post-baseline assessment (n = 1), or both (n = 16).
In the SOC group, 43 and 40 out of 92 patients were evaluable for the EORTC QLQ-C30 and FACT Lym-S analyses, respectively. Patients from this group were excluded from the EORTC QLQ-C30 analysis due to lack of baseline assessment (n = 20), lack of post-baseline assessment (n = 6), or lack of both (n = 23).
Additional data presented during the 2021 ASH Annual Meeting showed that with regard to the Functional Assessment of Cancer Therapy - Lymphoma Subscale (FACT-LymS), the difference in mean change between the 2 arms was -0.16 (range, -2.71 to 2.40). On the 126-day mark, the liso-cel group had a FACT-LymS mean change of 1.48 (range, -0.30 to 3.26), compared with 1.63 (range, -0.41 to 3.68) in the SOC group. Notably, for FACT-LymS, similar proportions of patients between the investigative and control arms experienced deterioration (24% and 29%, respectively) and improvement (47% and 43%) at month 6.
Overall QoL was either improved or maintained from baseline in patients with relapsed/refractory LBCL who received liso-cel as second-line treatment, Abramson concluded. These results were achieved despite only responders to salvage chemotherapy remaining in the SOC arm past day 64. These findings corroborated with previously reported HRQoL associated with liso-cel treatment.
References
Read more from the original source:
Liso-Cel Outperforms Standard Therapy in Improving QoL in Relapsed/Refractory LBCL - http://www.oncnursingnews.com/
- Mass. Law About Stem Cell Research - Massachusetts Trial ... [Last Updated On: August 22nd, 2014] [Originally Added On: August 22nd, 2014]
- Theres a New Anti-ALS Association Ice Bucket Challenge [Last Updated On: August 23rd, 2014] [Originally Added On: August 23rd, 2014]
- Expert: Catholic objections wont leave ALS fundraiser all wet [Last Updated On: August 23rd, 2014] [Originally Added On: August 23rd, 2014]
- Gene expression patterns in pancreatic circulating tumor cells revealed [Last Updated On: September 24th, 2014] [Originally Added On: September 24th, 2014]
- Inner Cell Mass - Embryonic Development & Stem Cells ... [Last Updated On: September 27th, 2014] [Originally Added On: September 27th, 2014]
- Mass production of placenta stem cells gets FDA approval ... [Last Updated On: September 27th, 2014] [Originally Added On: September 27th, 2014]
- Siamab Therapeutics Appoints Robert Mashal to Board of Directors [Last Updated On: October 9th, 2014] [Originally Added On: October 9th, 2014]
- Brain Tumor Stem Cell Lab - Massachusetts General Hospital ... [Last Updated On: October 9th, 2014] [Originally Added On: October 9th, 2014]
- 107.23 /$ (5 p.m.) [Last Updated On: October 15th, 2014] [Originally Added On: October 15th, 2014]
- Stem Cell Eye Treatment May Restore Vision [Last Updated On: October 16th, 2014] [Originally Added On: October 16th, 2014]
- Scientists Engineer Cancer-Killing Stem Cells [Last Updated On: October 26th, 2014] [Originally Added On: October 26th, 2014]
- Stem Cell Therapy, Stem Cell Biology at Mass General Hospital [Last Updated On: October 31st, 2014] [Originally Added On: October 31st, 2014]
- Harvard researchers genetically 'edit' human blood stem cells [Last Updated On: November 6th, 2014] [Originally Added On: November 6th, 2014]
- Human blood stem cells genetically 'edited' [Last Updated On: November 7th, 2014] [Originally Added On: November 7th, 2014]
- Critical Mass of Stem Cells Sets Off Embryonic Development ... [Last Updated On: November 12th, 2014] [Originally Added On: November 12th, 2014]
- Reprogramming cells, long term [Last Updated On: November 18th, 2014] [Originally Added On: November 18th, 2014]
- Pain and itch neurons grown in a dish [Last Updated On: November 25th, 2014] [Originally Added On: November 25th, 2014]
- Blood test could pick up risk of cancer five years in advance, say Harvard scientists [Last Updated On: November 28th, 2014] [Originally Added On: November 28th, 2014]
- The obesity pill that could replace exercise by turning 'bad' fat to 'good' [Last Updated On: December 9th, 2014] [Originally Added On: December 9th, 2014]
- Stem cells: The black box of reprogramming [Last Updated On: December 11th, 2014] [Originally Added On: December 11th, 2014]
- Canadian scientists crack stem cell reprogramming code [Last Updated On: December 11th, 2014] [Originally Added On: December 11th, 2014]
- Proteins drive cancer cells to change states [Last Updated On: December 16th, 2014] [Originally Added On: December 16th, 2014]
- Massachusetts (Stem Cell) - what-when-how [Last Updated On: February 3rd, 2015] [Originally Added On: February 3rd, 2015]
- New Organ Liver Prize Gathers Momentum [Last Updated On: February 4th, 2015] [Originally Added On: February 4th, 2015]
- MIT researchers develop glucose-responsive diabetes treatment [Last Updated On: February 11th, 2015] [Originally Added On: February 11th, 2015]
- Scientists develop novel technique for finding drugs to combat malaria [Last Updated On: February 11th, 2015] [Originally Added On: February 11th, 2015]
- Could we soon have man-made blood? [Last Updated On: March 10th, 2015] [Originally Added On: March 10th, 2015]
- Protein that repels immune cells protects transplanted pancreatic islets from rejection [Last Updated On: March 10th, 2015] [Originally Added On: March 10th, 2015]
- Researchers identify a vital protein that can determine head and brain development [Last Updated On: March 13th, 2015] [Originally Added On: March 13th, 2015]
- Biomedical engineer developing nanomaterial for healing broken bones [Last Updated On: March 18th, 2015] [Originally Added On: March 18th, 2015]
- Scientists engineer toxin-secreting stem cells to treat ... [Last Updated On: October 19th, 2015] [Originally Added On: October 19th, 2015]
- Cloning/Embryonic Stem Cells - Genome.gov [Last Updated On: October 19th, 2015] [Originally Added On: October 19th, 2015]
- Stem Cell Facts - University of Massachusetts Medical School [Last Updated On: July 27th, 2016] [Originally Added On: July 27th, 2016]
- Stem Cell FAQ - Massachusetts General Hospital, Boston, MA [Last Updated On: July 27th, 2016] [Originally Added On: July 27th, 2016]
- Stem-cell-based therapy promising for treatment of breast ... [Last Updated On: September 26th, 2016] [Originally Added On: September 26th, 2016]
- What Are Stem Cells? - Massachusetts General Hospital ... [Last Updated On: November 22nd, 2016] [Originally Added On: November 22nd, 2016]
- New England Cord Blood Bank - Cord Blood and Cord Tissue ... [Last Updated On: November 22nd, 2016] [Originally Added On: November 22nd, 2016]
- Stem cell controversy - Wikipedia [Last Updated On: December 1st, 2016] [Originally Added On: December 1st, 2016]
- From Stem Cells to Human Development - September 2016 ... [Last Updated On: December 4th, 2016] [Originally Added On: December 4th, 2016]
- X4 joins hands with Yale on rare disease program - FierceBiotech [Last Updated On: August 6th, 2017] [Originally Added On: August 6th, 2017]
- TGF-1: ALS Astrocytes' Secret Sauce? - ALS Research Forum [Last Updated On: August 6th, 2017] [Originally Added On: August 6th, 2017]
- CRISPR fixes disease gene in viable human embryos - Nature.com [Last Updated On: August 6th, 2017] [Originally Added On: August 6th, 2017]
- Current humanized mice not good models for studying stem cell transplants, say researchers - Scope (blog) [Last Updated On: August 27th, 2017] [Originally Added On: August 27th, 2017]
- Mouse Model of Human Immune System Inadequate for Stem Cell ... - Technology Networks [Last Updated On: August 27th, 2017] [Originally Added On: August 27th, 2017]
- ORGANOID - Science Magazine [Last Updated On: August 27th, 2017] [Originally Added On: August 27th, 2017]
- Asymmetrex Introduces New Contract Service For Producing ... - PR Web (press release) [Last Updated On: August 29th, 2017] [Originally Added On: August 29th, 2017]
- For Lowell native, stem cell match becomes a match as friends - Lowell Sun [Last Updated On: September 2nd, 2017] [Originally Added On: September 2nd, 2017]
- Lymphoma Patient's Brain Tumor Disappeared After She Received JCAR017, Study Reports - Lymphoma News Today [Last Updated On: September 2nd, 2017] [Originally Added On: September 2nd, 2017]
- Doubts raised about CRISPR gene-editing study in human embryos - Nature.com [Last Updated On: September 2nd, 2017] [Originally Added On: September 2nd, 2017]
- Alternate Methods for Preparing Pluripotent Stem Cells ... [Last Updated On: September 25th, 2017] [Originally Added On: September 25th, 2017]
- Cloning/Embryonic Stem Cells - National Human Genome ... [Last Updated On: July 5th, 2018] [Originally Added On: July 5th, 2018]
- Boston, MA, Stem Cell Transplant, Weston, Nantucket ... [Last Updated On: January 10th, 2019] [Originally Added On: January 10th, 2019]
- Chronic variable stress activates hematopoietic stem cells ... [Last Updated On: April 12th, 2019] [Originally Added On: April 12th, 2019]
- Massachusetts Stem Cells | Stem Cell TV [Last Updated On: September 10th, 2019] [Originally Added On: September 10th, 2019]
- Comparison of Merus N.V. (MRUS) and Sage Therapeutics Inc. (NASDAQ:SAGE) - MS Wkly [Last Updated On: October 23rd, 2019] [Originally Added On: October 23rd, 2019]
- Reviewing Cellectis S.A. (CLLS)'s and Magenta Therapeutics Inc. (NASDAQ:MGTA)'s results - MS Wkly [Last Updated On: October 23rd, 2019] [Originally Added On: October 23rd, 2019]
- New study reveals why breast cancer spreads to the brain - USC News [Last Updated On: October 23rd, 2019] [Originally Added On: October 23rd, 2019]
- Arkuda bags $44M to target progranulin and head off inherited dementia - FierceBiotech [Last Updated On: November 9th, 2019] [Originally Added On: November 9th, 2019]
- New Podcast Sponsored by Asymmetrex Increases Awareness to the Need for Stem Cell Dose in Stem Cell Treatments - PR Web [Last Updated On: November 9th, 2019] [Originally Added On: November 9th, 2019]
- Exercise found to block chronic inflammation in mice - Harvard Gazette [Last Updated On: November 9th, 2019] [Originally Added On: November 9th, 2019]
- Top Emerging Technologies of the Year - Technowize [Last Updated On: December 29th, 2019] [Originally Added On: December 29th, 2019]
- Firm adds a new wrinkle to anti-aging products - Williamson Daily News [Last Updated On: January 5th, 2020] [Originally Added On: January 5th, 2020]
- Where Are They Now? Top 3 Biotech Startups From NextGen Bio Class of 2018 - BioSpace [Last Updated On: January 10th, 2020] [Originally Added On: January 10th, 2020]
- 10 Of The Biggest World Revelations In The 21st Century - World Atlas [Last Updated On: February 29th, 2020] [Originally Added On: February 29th, 2020]
- Infrared Laser Treatment of TBI, PTSD, and Depression: An Expert Perspective - Psychiatry Advisor [Last Updated On: April 3rd, 2020] [Originally Added On: April 3rd, 2020]
- Startup targets glioblastoma tumors with CAR-T therapy - FierceBiotech [Last Updated On: May 28th, 2020] [Originally Added On: May 28th, 2020]
- Massachusetts Eye and Ear Enters Licensing Agreement with Biogen to Develop Treatment for Inherited Retinal Disorder - Newswise [Last Updated On: July 2nd, 2020] [Originally Added On: July 2nd, 2020]
- Targeted Therapy for Non-Hodgkin Lymphoma: Current Progress and Future Plans - Cancer Therapy Advisor [Last Updated On: September 5th, 2020] [Originally Added On: September 5th, 2020]
- Be Biopharma debuts with $52M to advance engineered B-cell therapies - FierceBiotech [Last Updated On: October 24th, 2020] [Originally Added On: October 24th, 2020]
- NurOwn May Be Given to Early ALS Patients in US Who Finished Phase... - ALS News Today [Last Updated On: December 20th, 2020] [Originally Added On: December 20th, 2020]
- Orchard Therapeutics Outlines Comprehensive Presence at 2021 WORLDSymposium - GlobeNewswire [Last Updated On: February 1st, 2021] [Originally Added On: February 1st, 2021]
- How Coronavirus Damages Lung Cells Within Mere Hours And What Drugs Could Halt COVID-19 Infection - SciTechDaily [Last Updated On: February 1st, 2021] [Originally Added On: February 1st, 2021]
- On systemic sources of early life stress, and empathetic responses - MIT News [Last Updated On: June 6th, 2021] [Originally Added On: June 6th, 2021]
- Asymmetrex Will Present a New Test for Therapeutic Stem Cell Potency at the ISSCR 2021 Annual Meeting - PRNewswire [Last Updated On: June 23rd, 2021] [Originally Added On: June 23rd, 2021]
- Infertility: Men account for at least half of cases. So why have women shouldered the blame? - The Irish Times [Last Updated On: June 23rd, 2021] [Originally Added On: June 23rd, 2021]
- cGVHD Paradigm Gains Systemic Options Beyond Steroids, But Real-World Data Are Required - OncLive [Last Updated On: October 28th, 2021] [Originally Added On: October 28th, 2021]
- Stem cells: Sources, types, and uses - Medical News Today [Last Updated On: December 24th, 2021] [Originally Added On: December 24th, 2021]
- January 2022: 2021 Papers of the year - Environmental Factor Newsletter [Last Updated On: January 5th, 2022] [Originally Added On: January 5th, 2022]
- MorphoSys and Incyte Announce Swissmedic Temporary Approval of Minjuvi(R) (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults... [Last Updated On: March 25th, 2022] [Originally Added On: March 25th, 2022]
- Takeda and the New York Academy of Sciences Announce 2022 Innovators in Science Award Winners - The New York Academy of Sciences [Last Updated On: April 6th, 2022] [Originally Added On: April 6th, 2022]